Next Article in Journal
Papillary Thyroid Carcinoma Variants are Characterized by Co-dysregulation of Immune and Cancer Associated Genes
Next Article in Special Issue
The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy
Previous Article in Journal
Electrochemotherapy Causes Caspase-Independent Necrotic-Like Death in Pancreatic Cancer Cells
Previous Article in Special Issue
p21cip1/waf1 Coordinates Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress
Open AccessReview

p21 in Cancer Research

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
Department of Molecular Biology & Biochemistry, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1178;
Received: 19 July 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published: 14 August 2019
(This article belongs to the Special Issue p21 – An Underestimated Driver for Cancers)
p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies. View Full-Text
Keywords: p21; cancer; therapeutic approach; p53; gene editing p21; cancer; therapeutic approach; p53; gene editing
Show Figures

Figure 1

MDPI and ACS Style

Shamloo, B.; Usluer, S. p21 in Cancer Research. Cancers 2019, 11, 1178.

AMA Style

Shamloo B, Usluer S. p21 in Cancer Research. Cancers. 2019; 11(8):1178.

Chicago/Turabian Style

Shamloo, Bahar; Usluer, Sinem. 2019. "p21 in Cancer Research" Cancers 11, no. 8: 1178.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop